The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.
BioPharma Dive: Revolution pancreatic cancer drug nearly doubles survival in key trial
The subject of buyout rumors this year, Revolution posted Phase 3 results one analyst called a “game changer” in a tough-to-treat tumor.
Fierce Biotech: AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. | After dropping headline-grabbing phase 3 ...
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises
Case Western Reserve University: How a microscopic fungus could lead to a breakthrough in oral cancer research
Microscopic fungus may have more to do with oral cancer and aging than first thought, according to new research from Case Western Reserve University. Pushpa Pandiyan, an associate professor of ...
How a microscopic fungus could lead to a breakthrough in oral cancer research
BioPharma Dive: AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
Featured at this year’s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and several targeted medicines for lung tumors.
AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
CNBC: Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial
Revolution Medicines said its pancreatic cancer drug daraxonrasib succeeded in a Phase 3 trial. RevMed said its drug almost doubled the typical length of survival and slashed the risk of death by 60% ...